Skip to main content

Advertisement

SpringerLink
Log in

The risk of gastric cancer in carriers of CHEK2 mutations

  • Original Article
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

CHEK2 is a tumor suppressor gene whose functions are central to the induction of cell cycle arrest and apoptosis following DNA damage. Mutations in CHEK2 have been associated with cancers at many sites, including breast and prostate cancers, but the relationship between CHEK2 and gastric cancer has not been extensively studied. In Poland, there are four known founder alleles of CHEK2; three alleles are protein truncating (1100delC, IVS2G>A, del5395) and the other is a missense variant (I157T). We examined the frequencies of four Polish founder mutations in the CHEK2 gene in 658 unselected gastric cancer patients, in 154 familial gastric cancer patients and in 8,302 controls. A CHEK2 mutation was seen in 57 of 658 (8.7 %) unselected patients with gastric cancer compared to 480 of 8,302 (5.8 %) controls (OR 1.6, p = 0.004). A CHEK2 mutation was present in 19 of 154 (12.3 %) familial cases (OR = 2.3, p = 0.001). The odds ratio for early onset (<50 years) gastric cancer was higher (2.1, p = 0.01), than for cases diagnosed at age of 50 or above (OR 1.4, p = 0.05). Truncating mutations of CHEK2 were associated with higher risk (OR = 2.1, p = 0.02) than the missense mutation I157T (OR = 1.4, p = 0.04). CHEK2 mutations predispose to gastric cancer, in particular to young-onset cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yaghoobi M, Bijarchi R, Narod SA (2010) Family history and the risk of gastric cancer. Br J Cancer 102:237–242

    Article  PubMed  CAS  Google Scholar 

  2. Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, Oliveira C, Tischkowitz M, Olschwang S, Gallinger S, Lynch H, Green J, Ford J, Pharoah P, Fernandez B, Huntsman D (2007) Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 297(21):2360–2372

    Article  PubMed  CAS  Google Scholar 

  3. Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, Zhang X, Annan RS, Lu Q, Faucette LF, Scott GF, Li X, Carr SA, Johnson RK, Winkler JD, Zhou BB (1999) Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18(28):4047–4054

    Article  PubMed  CAS  Google Scholar 

  4. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ (2000) Ataxia telangiectasia–mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 97:10389–10394

    Article  PubMed  CAS  Google Scholar 

  5. Bartek J, Lukas J (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3(5):421–429

    Article  PubMed  CAS  Google Scholar 

  6. Ahn J, Urist M, Prives C (2004) The Chk2 protein kinase. DNA Repair (Amst) 3(8–9):1039–1047

    Article  CAS  Google Scholar 

  7. Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, Debniak T, Masojć B, Jakubowska A, Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P, Bar K, Klijer R, Zdrojowy R, Małkiewicz B, Borkowski A, Borkowski T, Szwiec M, Narod SA, Lubiński J (2006) A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 43(11):863–866

    Article  PubMed  CAS  Google Scholar 

  8. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA (1999) Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528–2531

    Article  PubMed  CAS  Google Scholar 

  9. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N (2002) CHEK2-breast cancer consortium. Low-penetrance susceptibility to breast cancer due to CHEK2(*) 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31(1):55–59

    Article  PubMed  CAS  Google Scholar 

  10. Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A, Elstrodt F, van den Bos R, de Snoo A, Fat GT, Brekelmans C, Jagmohan S, Franken P, Verkuijlen P, van den Ouweland A, Chapman P, Tops C, Möslein G, Burn J, Lynch H, Klijn J, Fodde R, Schutte M (2003) The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 72(5):1308–1314

    Article  PubMed  CAS  Google Scholar 

  11. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymanska A, Szymanska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubinski J (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75(6):1131–1135

    Article  PubMed  CAS  Google Scholar 

  12. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomäki K, Nevanlinna H (2001) p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 61(15):5718–5722

    PubMed  CAS  Google Scholar 

  13. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 71(2):432–438

    Article  PubMed  CAS  Google Scholar 

  14. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12):1379–1388

    Article  PubMed  CAS  Google Scholar 

  15. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN, Liu W (2003) Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72(2):270–280

    Article  PubMed  CAS  Google Scholar 

  16. Seppala EH, Ikonen T, Mononen N, Autio V, Rokman A, Matikainen MP, Tammela TL, Schleutker J (1970) CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003(89):1966–1970

    Google Scholar 

  17. Cybulski C, Huzarski T, Górski B, Masojc B, Mierzejewski M, Debniak T, Gliniewicz B, Matyjasik J, Zlowocka E, Kurzawski G, Sikorski A, Posmyk M, Szwiec M, Czajka R, Narod SA, Lubinski J (2004) A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 64:2677–2679

    Article  PubMed  CAS  Google Scholar 

  18. Kleibl Z, Havranek O, Hlavata I, Novotny J, Sevcik J, Pohlreich P, Soucek P (2009) The CHEK2 gene I157T mutation and other alterations in its proximity increase the risk of sporadic colorectal cancer in the Czech population. Eur J Cancer 45:618–624

    Article  PubMed  CAS  Google Scholar 

  19. Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, Nevanlinna H (2006) CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet 43:e34

    Article  PubMed  CAS  Google Scholar 

  20. Cybulski C, Wokołorczyk D, Kładny J, Kurzawski G, Suchy J, Grabowska E, Gronwald J, Huzarski T, Byrski T, Górski B (2007) D Ecedil Bniak T, Narod SA, Lubiński J. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur J Hum Genet 15(2):237–241

    Article  PubMed  CAS  Google Scholar 

  21. Brennan P, McKay J, Moore L, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chow WH, Rothman N, Chabrier A, Gaborieau V, Odefrey F, Southey M, Hashibe M, Hall J, Boffetta P, Peto J, Peto R, Hung RJ (2007) Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study. Hum Mol Genet 16(15):1794–1801

    Article  PubMed  CAS  Google Scholar 

  22. Cybulski C, Masojc B, Oszutowska D, Jaworowska E, Grodzki T, Waloszczyk P, Serwatowski P, Pankowski J, Huzarski T, Byrski T, Górski B, Jakubowska A, Debniak T, Wokolorczyk D, Gronwald J, Tarnowska C, Serrano-Fernández P, Lubinski J, Narod SA (2008) Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis 29(4):762–765

    Article  PubMed  CAS  Google Scholar 

  23. Cybulski C, Wokołorczyk D, Jakubowska A et al (2011) Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 29:3747–3752

    Article  PubMed  CAS  Google Scholar 

  24. Cybulski C, Wokołorczyk D, Kluźniak W, Jakubowska A, Górski B, Gronwald J, Huzarski T, Kashyap A, Byrski T, Dębniak T, Gołąb A, Gliniewicz B, Sikorski A, Switała J, Borkowski T, Borkowski A, Antczak A, Wojnar L, Przybyła J, Sosnowski M, Małkiewicz B, Zdrojowy R, Sikorska-Radek P, Matych J, Wilkosz J, Różański W, Kiś J, Bar K, Bryniarski P, Paradysz A, Jersak K, Niemirowicz J, Słupski P, Jarzemski P, Skrzypczyk M, Dobruch J, Domagała P, Narod SA, Lubiński J (2012) An inherited NBN mutation is associated with poor prognosis prostate cancer. Br J Cancer 13 doi: 10.1038/bjc.2012.486

  25. Ingvarsson S, Sigbjornsdottir BI, Huiping C, Hafsteinsdottir SH, Ragnarsson G, Barkardottir RB, Arason A, Egilsson V, Bergthorsson JT (2002) Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res 4(3):R4

    Article  PubMed  Google Scholar 

  26. Kimura K, Shinmura K, Yoshimura K, Shimizu K, Katai H, Beppu Y, Moriya H, Yokota J (2000) Absence of germline CHK2 mutations in familial gastric cancer. Jpn J Cancer Res 91(9):875–879

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland

    Urszula Teodorczyk, Cezary Cybulski, Dominika Wokołorczyk, Anna Jakubowska & Jan Lubiński

  2. Clinic of Gastroenterology, Pomeranian Medical University, Szczecin, Poland

    Teresa Starzyńska, Małgorzata Ławniczak, Katarzyna Ferenc & Krzysztof Marlicz

  3. Department of Pathology, Pomeranian Medical University, Szczecin, Poland

    Paweł Domagała

  4. Clinic of General Surgery, University Hospital, Bydgoszcz, Poland

    Zbigniew Banaszkiewicz

  5. Beskidian Center of Oncology, Bielsko Biała, Poland

    Rafał Wiśniowski

  6. Women’s College Research Institute, 790 Bay, Toronto, ON, M5G 1N8, Canada

    Steven A. Narod

Authors
  1. Urszula Teodorczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cezary Cybulski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dominika Wokołorczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Jakubowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Teresa Starzyńska
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Małgorzata Ławniczak
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paweł Domagała
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katarzyna Ferenc
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Krzysztof Marlicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zbigniew Banaszkiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Rafał Wiśniowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Steven A. Narod
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jan Lubiński
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven A. Narod.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Teodorczyk, U., Cybulski, C., Wokołorczyk, D. et al. The risk of gastric cancer in carriers of CHEK2 mutations. Familial Cancer 12, 473–478 (2013). https://doi.org/10.1007/s10689-012-9599-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-012-9599-2

Keywords

Search

Navigation